Wegovy In a clinical trial of adults with overweight or obesity (without diabetes), once-weekly semaglutide (Wegovy) led to significantly greater weight loss over 68 weeks compared to once-daily liraglutide (Saxenda)
Novos obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021
To see what sets Brello apart and explore its evidence-based weight loss approach, explore the 2025 science behind Brello Health
Because both mitochondrial and cytosolic GSTs exist as dimers, and only heterodimers form between members of the same class, the second subfamily component of the enzyme dimer is denoted with a hyphen, followed by an additional Arabic numeral
Retatrutide is a triple agonist meaning it acts on three hormone pathways (GLP-1, GIP, and glucagon receptors)
Dhirmalani, a Replenza advisory board member